Current controversies in the treatment of stage I seminoma center on the relative roles of surveillance, adjuvant radiotherapy (RT), and adjuvant single-agent chemotherapy. Surveillance has been studied in over 800 patients,
Gunar K. Zzagars, MD
Advertisement
Articles by Gunar K. Zzagars, MD
Advertisement
Latest Updated Articles
- Controversies in the Management of Stage I Seminoma
August 1st 1998
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
3
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
4
TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
5